Full Press Release Details
Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting
Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial Applications
Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan
Diego, CA - August 6, 2025 - Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"),
a leader in AI-powered scent digitization, today announced it has secured a three-year subscription-based order valued at $2.1 million
with ASE Technology Holding Co., Ltd. ("ASEH"), the world's largest provider of semiconductor assembly and test
services. The agreement represents the first commercial success of Ainos' proprietary AI Nose platform in semiconductor manufacturing.
the agreement, Ainos will deploy 1,400 AI Nose units across ASEH's three major manufacturing sites in Taiwan-Kaohsiung, Zhongli,
and SPIL. Through this rollout, Ainos will launch its SmellTech-as-a-Service model to enhance ASEH's smart manufacturing initiatives,
enabling AI-powered scent intelligence designed to improve process stability, support predictive maintenance, and increase operational
milestone marks the first revenue-generating order for AI Nose in the industrial market. It is the second commercial success, following
its first revenue in the senior care sector during 1Q 2025. Together, these developments validate Ainos' strategic focus on labor-constrained,
sensor-intensive environments where traditional sensing modalities fall short.
executing with speed and precision," said Eddy Tsai, Chairman and CEO of Ainos. "This initial deployment proves AI Nose's
real-world value-and it's just the beginning. We're expanding SmellTech into high-impact industrial applications. Next,
we'll begin pilot deployments at seven sites in Japan with our robotics partner ugo, Inc., strengthening our presence in
that market. In Taiwan, we're advancing multi-site rollouts with Kenmec, and Solomon. We're actively delivering
on our global commercialization roadmap, and the second half of 2025 will be a defining chapter as we scale across Asia."
agreement follows Ainos' previous announcement of an expanded strategic partnership with ASEH. Today's milestone represents
the transition of that partnership into commercial deployment, reinforcing customer confidence and platform maturity.
identified the ASEH deployment as a core deliverable in its 90-day execution plan, outlined in its previous corporate update. The plan
focuses on converting strategic partnerships into active deployments, generating recurring revenue, and accelerating data acquisition
to improve model performance across real-world environments. Deployments in Japan and Taiwan support this data flywheel, strengthening
Ainos' AI model training pipeline for global applications.
global electronic nose (e-Nose) market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032, with industrial monitoring
leading demand. Ainos is positioning AI Nose not just as a sensor, but as a trainable AI platform-capable of digitizing scent into
machine-readable Smell ID data. Powered by its proprietary smell language model (SLM), AI Nose shows exciting potential to become a scent-based
LLM, capable of classifying, interpreting, and contextualizing complex olfactory signals.
is emerging as AI's next token-just as words power LLMs and pixels fuel vision AI, scent data will define the next wave of
machine perception," Tsai added. "With AI Nose, we're understanding, classifying, and acting on olfactory information."
agreement further strengthens Ainos' footprint in Asia's advanced manufacturing base and reinforces its position as a first
mover in SmellTech-an underdeveloped but high-impact frontier in artificial intelligence. Headquartered in the U.S. and working
alongside partners across Taiwan, Japan, and the global industrial ecosystem, Ainos is accelerating the commercialization of AI-powered
Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision
MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts
analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by
a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant
alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing
scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and
smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics,
smart factories, and healthcare. The company also develops VELDONA , a low-dose oral interferon targeting rare, autoimmune, and infectious
diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn
more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to
ASE Technology Holding Co., Ltd.
Technology Holding is the leading provider of semiconductor manufacturing services in assembly and test. ASEH develops and offers complete
turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing
services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological
capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and
Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services.
For more information, please visit https://www.aseglobal.com.
statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking
statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends,
which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other
events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of
important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated
by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur
net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product
development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates
through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain
and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current
and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability
to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section
of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to
risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking
statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes
no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.